Abstract
We describe a Bayesian methodology for estimating the cost-effectiveness of a new treatment compared to a standard in a clinical trial, when censoring of survival, the effectiveness variable, induces censoring of total cost. The statistical model assumes that survival follows a Weibull distribution and that total health care cost follows a gamma distribution whose mean has a linear regression on survival time. We summarize the posterior distributions of key parameters by importance sampling. We illustrate the method with an analysis of data from a randomized clinical trial of a treatment for cardiovascular disease.
Original language | English (US) |
---|---|
Pages (from-to) | 1297-1309 |
Number of pages | 13 |
Journal | Statistics in Medicine |
Volume | 23 |
Issue number | 8 |
DOIs | |
State | Published - Apr 30 2004 |
Keywords
- Bayesian inference
- Clinical trials
- Cost-effectiveness ratios
- Importance sampling
- Net monetary benefit
ASJC Scopus subject areas
- Epidemiology
- Statistics and Probability